Summit Therapeutics Inc vs State Street SPDR S&P Homebuilders ETF — how do they compare? Summit Therapeutics Inc trades at $14.57 (market cap $10.48B), while State Street SPDR S&P Homebuilders ETF trades at $105.91. The key difference: State Street SPDR S&P Homebuilders ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | XHB | |
|---|---|---|
Market Cap | $10.48B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $29.32 | $121.36 |
52-Week Low | $13.05 | $94.86 |
Enterprise Value | $9.90B | — |
Trailing returns across standard periods
Latest headlines on both assets
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →